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Objectives 
To determine the proportion of children with cerebral palsy (CP) and cytomegalovirus (CMV) DNA 
detected retrospectively in their newborn screening cards (NBSC), to compare the proportion of 
children with CMV DNA in their NBSC across spastic subtypes of CP, and to compare the sex and 
other characteristics of children with CP and CMV detected on their NSBC with those in whom CMV 
DNA was not detected. 
Study design 
Retrospective observational study. Data were extracted from patient records on children with CP 
(birth years 1996-2014) from 2 Australian state CP registers and state-wide paediatric rehabilitation 
services with consent. NBSCs were retrospectively analyzed for CMV DNA by nested polymerase 
chain reaction (PCR) using primers against gB. Positive samples were validated using real time PCR 
for CMV UL83. 
Results 
Of 401 children recruited, 323 (80.5%) had an available NBSC. Of these, 31 (9.6%; 95% CI, 6.8-13.3) 
tested positive for CMV DNA by nested PCR for CMV gB, of whom 28 (8.7%; 95% CI, 6.1-12.2) also 
had CMV DNA detected by real-time PCR for CMV UL83. Detection of CMV DNA was significantly 
associated with epilepsy, but not with clinical or epidemiologic characteristics, including sex and 
pattern of spasticity. 
Conclusions 
CMV viremia in the newborn period, indicating congenital CMV infection, is highly prevalent among 
children with CP. Further research is needed to investigate the mechanisms and contribution of 
congenital CMV to the causal pathways to CP. 
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Cytomegalovirus (CMV) is a common herpesvirus that can cross the placenta, infect the fetus and 
cause damage to the developing brain.1 Congenital CMV (cCMV) infection has been estimated to 
occur in approximately 0.7% of newborn infants,2, 3 of whom 10%-15% exhibit signs of infection at 
birth. These infants are at increased risk of permanent neurodevelopmental disabilities including 
cerebral palsy (CP). It is estimated that a further 10%-15% of children who are asymptomatic at birth 
will go on to develop neurologic sequelae beyond the neonatal period, predominantly late-onset 
hearing loss.3, 4, 5 
CP is the most common physical disabilty of childhood, and has been associated with a number of 
risk factors, including intrauterine infections such as cCMV.6 Despite this known association, and 
estimates of neurologic disability from cCMV, few data describe the prevalence and epidemiology of 
CP associated with cCMV. Defining the role of cCMV as a risk factor for CP is important because it is 
the most common intrauterine infection in developed countries, is potentially preventable, and 
antiviral therapy postnatally can reduce the severity of adverse neurologic outcomes.7 The recent 
outbreaks of Zika virus in South America and French Polynesia and their assocation with birth 
defects including microcephaly further highlight the importance of intrauterine infection in 
neurodevelopmental disability.8 
We have reported previously a retrospective population-based study using data from the Australian 
CP Register (ACPR). We found that 1.5% of children had cCMV (confirmed or probable) reported as 
an attributable contributing cause of their CP.9 Here, female children were over-represented, as 
were younger mothers, and there was a higher prevalence of spastic quadriplegia (73% of children 
with spastic CP) and severe functional mobility limitations. Similar findings have been reported in 
small case series in the US and Europe.10, 11 In the absence of a newborn screening program for 
cCMV in Australia, we hypothesized that our study may have underascertained the proportion of 
children with CP who had cCMV. 
To test our hypothesis, and validate findings from the retrospective population-based study, we 
aimed to determine the proportion of children with CMV DNA retrospectively detected in their 
newborn screening card (NBSC) by molecular testing (polymerase chain reaction [PCR]) among a 
group of children with CP born in New South Wales (NSW) and the Australian Capital Territory (ACT). 
Secondary objectives were to use CP register data to compare the proportion of children with CMV 
DNA on their NBSCs among children with spastic quadriplegia compared with other forms of spastic 
CP and to compare the sex and clinical profile of children with CP and CMV detected on their NSBC 
with those in which CMV DNA was not detected. 
Methods 
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Parents or guardians of children (aged less than 18 years) with CP (birth years 1996-2014) from the 
NSW and ACT CP registers, or the state-wide disability services provider Cerebral Palsy Alliance, or 
the CP outpatient clinic at the Children's Hospital at Westmead, provided informed consent for NBSC 
testing for cCMV and extraction of registry data. This study was approved by the NSW Population 
and Health Services Research Ethics Committee (EC00410), the Cerebral Palsy Alliance Human 
Research Ethics Committee (EC00402), and by the University of Sydney Human Research Ethics 
Committee. 
Data extracted from the CP Registers included cCMV reported as an attributable cause of CP, sex, 
gestational age, birthweight, plurality, maternal age at time of birth, parity (live births and stillbirths 
of 20 weeks or more, excluding co-multiples of the case), predominant type of CP at 5 years of age, 
and functional mobility. Data on symptoms and signs of cCMV in the newborn period were 
unavailable because they are not part of the CP register dataset. Functional mobility was described 
using the Gross Motor Function Classification System.12Associated impairment data included 5 
domains: intellect, (1) no impairment (IQ of less than 70 or so described), (2) mild impairment (IQ 50-
69 or so described), and (3) moderate to severe impairment (IQ of less than 35-49 or so described); 
vision, some impairment, which in this context includes use of glasses; hearing, some impairment, 
which in this context includes conductive hearing loss; bilateral deafness describes a 
severe/profound hearing loss for both ears, where conversational speech is inaudible; speech, some 
impairment describes any expressive speech and language difficulty, and nonverbal is used to 
describe no or severely limited verbal expressive communication and/or reliance 
predominantly/exclusively on augmentative and alternative communication strategies and the 
presence/absence of epilepsy, defined as 2 or more afebrile seizures before 5 years of age; and does 
not include neonatal seizures. CP register data are obtained from treating specialist clinician records 
with associated impairments measured by standard methodologies as selected by the treating 
clinician. Register data are reconfirmed with the treating clinician when the child is 5 years of age. 
For participating children less than 5 years of age (n = 23/401; 5.8%), data from the initial record of 
CP registration were used. We deidentified each child's clinical record and NBSC by allocating a 
unique study number. 
NBSC were collected from the NSW Newborn Screening Program at the Children's Hospital at 
Westmead. The NBSC testing was completed blinded to the child's clinical status. CMV DNA was 
extracted from 4 punches per NSBC using the QIAamp DNA Micro Kit (Qiagen, Stanford, 
California)13 according to the methodology of the National Association of Testing Authorities 
accredited diagnostic laboratory at Children's Hospital at Westmead, which uses a modification of a 
published protocol14 and rigorous attention to prevent contamination, including a minimum of 28 
disks punched from a blank filter paper between samples. A 10-µL sample of each extract was 
subjected to nested CMV DNA PCR testing using 2 primer sets to amplify a segment of the 
glycoprotein B gene (UL58) with minor modifications to the published protocol and a lower limit of 
detection was approximately 10 viral copies/mL.14 CMV-positive DNA and negative controls were 
included with every reaction, and confirmed the absence of cross contamination. Positive results 
were validated by a real-time PCR assay for CMV UL83 gene, with human glyceraldehyde-3-
phosphate dehydrogenase gene as an internal control as published15using a separate punch from the 
NBSC. The lower limit of detection of this assay was 100 copies/mL, with 1 copy of CMV being 
roughly equivalent to 0.9 international units. 
We compared proportions between groups using the χ2 or Fisher exact test where appropriate to 
analyse the crude relationship between characteristics of the children who had positive and negative 
cCMV test results. We investigated associated impairments between individuals with no impairment 
and those with the most severe level of impairment only. In a post hoc analysis to measure 
recruitment bias, we compared the characteristics of participants in this study with those children 
recorded on population state registers in the ACPR using χ2 or Fisher extact test where 
appropriate. P < .05 was considered significant. Data were analysed using SPSS Statistics version 
23.0.0 (SPSS Inc, Chicago, Illinois). 
Results 
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A total of 401 individuals with CP were recruited, of whom 323 (80.5%) had an available NBSC 
(Figure; available at www.jpeds.com). Of these, 31 (9.6%; 95% CI, 6.8-13.3) tested positive for CMV 
DNA (cCMV-positive cases) in NBSC by nested PCR for CMV gB, of whom 28 (8.7%; 95% CI, 6.1-12.2) 
had CMV DNA also detected by real time PCR for CMV UL83. 
We next compared the characteristics of participants using extracted registry data, according to their 
NBSC test result for CMV DNA. There were 140 female children (43.5%) in this study (Table I), and a 
similar proportion of female cases within both the cCMV positive and negative groups (45.2 vs 
43.3%; P = .851). No differences were found between groups for maternal age (  31 years vs 31 
years; P = .968) plurality, birthweight, or gestational age (Table I). 
Table ICharacteristics of children with CP the NBSC CMV PCR test result 
 
Total NBSC tested CMV Positive CMV Negative P 
 
No. (%) No. (%) No. (%) 
 
CP cases by CMV test result 323(100) 31(9.6) 292(90.4)  
Sex n = 322 n = 31 n = 291 .85 
 Male 182(57) 17(55) 165(57) 
 Female 140(43) 14(45) 126(43) 
Gestational age (w) n = 321 n = 30 n = 291 .75 
 <37 121(38) 12(40) 109(37) 
 ≥37 200(62) 18(60) 182(63) 
 Mean [SD, range]  36.3(5) 31-41 36.0(5.1) 31-41 
Birthweight (g) n = 316 n = 30 n = 290 .91 
 <1500 63(20) 4(13) 61(21) 
 1500-2499 54(17) 8(27) 47(16) 
 ≥2500 199(63) 18(60) 182(63) 
 Mean (SD)  2667(973) 2690(1058) 
 Range  1693-3639 1631-3747 
Maternal age (y) n = 278 n = 23 n = 255 .97 
 ≤20 6(2) 1(4) 5(2) 
 21-34 199(72) 17(74) 182(71) 
 35+  5(22) 68(27) 
 Mean (SD), range 73(26) 31.2(4.9), 26-36 31.1(5.1), 26-36 
Parity n = 254 n = 22 n = 232 .27 
 0 127(50) 14(64) 113(49) 
 ≥1 127(50) 8(36) 119(51) 
Functional mobility n = 290 n = 25 n = 265 .92 
 GMFCS I-III 218(75) 19(76) 199(75) 
 GMFCS IV-V 72(25) 6(24) 66(25) 
Type and topography n = 279 n = 28 n = 276 .13 
 Spastic 245[82] 26[92] 223[81] 
  Hemiplegia 114(46) 14(54) 100(46) 
  Diplegia 68(28) 5(19) 63(29) 
  Triplegia 5(2) 1(4) 4(2) 
  Quadriplegia 58(24) 6(23) 54(23) .80 
 Ataxic 23[8] 0[0.0] 23[8] 
 Dyskinetic 17[5] 1[4] 16[6] 
 Hypotonic 15[5] 1[4] 14[5] 
Speech n = 256 n = 23 n = 233 .94 
 No impairment 95(37) 6(26) 89(38) 
 Some impairment 116(45) 14(61) 102(44) 
 Nonverbal 45(18) 3(13) 42(18) 
Intellectual impairment n = 251 n = 22 n = 229 .77 
 No impairment 151(60) 13(59) 138(60) 
 Some impairment 52(21) 6(27) 46(20) 
 Moderate/severe impairment 48(19) 3(13) 45(20) 
Hearing impairment n = 274 n = 24 n = 250 .76 
 No impairment 238(87) 18(75) 220(88) 
 Some impairment 23(8) 3(12) 20(8) 
 Bilateral deafness 13(5) 3(12) 10(4) 
Visual impairment n = 253 n = 23 n = 230 .35 
 No impairment 161(64) 16(70) 145(63) 
 Some impairment 84(33) 7(30) 77(33) 
 Functionally blind 8(3) 0(0.0) 8(3) 
Epilepsy n = 278 n = 25 n = 253 .04** 
 None 207(75) 15(60) 192(75) 
 Resolved 8(2) 0(0) 8(3) 
 Epilepsy 63(23) 10(40) 53(21) 
GMFCS, Gross Motor Function Classification System. 
() = % of cases excluding unknown/missing data. [%] proportion of CP types excluding 
unknown/missing. 
Italicized data represent subgroups of Spastic CP. 
*P < .05 
Even though spasticity was the most common type of CP across both groups, there were no 
differences in spastic subytypes between the cCMV-positive and cCMV-negative groups (Table I). We 
next compared the functional mobility and associated impairments reported for the cCMV-positive 
and cCMV-negative groups. With the exception of epilepsy, which was over-represented among the 
cCMV-positive group (40% vs 20.9%; P < .05), there were no differences between the 2 groups in 
relation to any comorbidities examined (Table I). Although proportionally more children in the cCMV 
positive group had hearing loss and deafness, the difference was not significant. 
In a post hoc analysis to investigate possible recruitment bias, we investigated whether differences 
between the observed assocations (female sex, CP subtype, and comorbidities) with cCMV status in 
our previous study,9 and the results from this study could be explained by differences in the study 
populations. After analyzing key factors (sex, CP type and topography, functional mobility, and 
associated impairments) we found no significance between these 2 groups (Table II). We also 
compared the proportion of children with a CP register record of confirmed or probable cCMV with 
the finding of 1.5% from our previous study of ACPR data.9 Four children (1.2%) had an existing 
record of cCMV as an attributable cause of their CP together with reported laboratory evidence to 
support a diagnosis of probable or confirmed cCMV as previously defined,9 of whom 2 had CMV DNA 
detected by retrospective analysis of their NBSC in this study. Last, we reviewed the best available 
demographic, neonatal, and clinical data (sex, gestational age, birth weight, plurality, parity, 
functional mobility, and associated impairments) for the Australian Capital Territory and NSW CP 
Register group as a whole for the same birth years (n = 1881) and the participant group (n = 401). 
There were no differences observed between the groups. 
Table IICharacteristics of children with CP** 
 
Population CP 
Registers 
 
1993-2003, n (%) 
Children with CP, with NBSC tested for 
CMV DNA n (%) P 
Registrants n = 2265 n = 323  
Sex n = 2265 n = 322 .97 
 Male 1278(56) 182(56) 
 Female 987(44) 140(43) 
CP type and topography n = 2245 n = 279 .12 
 Spastic 1913[85] 245[82] 
  Hemiplegia 735(38) 114(46) 
  Diplegia 689(36) 68(28) 
  Triplegia 60(3) 5(2) 
  Quadriplegia 429(22) 58(24) .69 
 Ataxic 145[6] 23[8] 
 Dyskinetic 143[6] 17[5] 
 Hypotonic 44[2] 15[5] 
Functional mobility n = 1114†† n = 290 .11 
 GMFCS I-III 784(70) 218(75) 
 GMFCS IV-V 330(30) 72(25) 
Speech n = 1758†† n = 256 .08 
 No impairment 701(40) 95(37) 
 Some impairment 588(33) 116(45) 
 Nonverbal 469(27) 45(18) 
Intellectual impairment n = 1548†† n = 251 .44 
 No impairment 960(62) 151(60) 
 Some impairment 196(13) 52(21) 
 Moderate/severe 392(25) 48(19) 
impairment 
Hearing impairment n = 1771†† n = 274 .09 
 No impairment 1559(88.0) 238(87) 
 Some impairment 162(9) 23(8) 
 Bilateral deafness 50(3) 13(5) 
Visual impairment n = 1616†† n = 253 .07 
 No impairment 955(59) 161(64) 
 Some impairment 565(35) 84(33) 
 Functionally blind 96(6) 8(3) 
Epilepsy n = 1847†† n = 278 .09 
None 1250(68) 207(74) 
Resolved 29(2) 8(2) 
Epilepsy 568(30) 63(23) 
() = % of cases excluding unknown/missing data. [%] proportion of CP types excluding 
unknown/missing. 
Italicized data represent subgroups of Spastic CP. 
*As reported to the (i) population CP Registers (South Australia, Victoria and Western 
Australian)9compared with the (ii) study participants with CP who had their newborn screening card 
(NBSC) tested for CMV DNA. 
†Excludes South ACPR data. 
Discussion 
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This retrospective study identified that 9.6% (95% CI, 6.8%-13.3%) of children with CP had CMV DNA 
detected in their NBSC, confirming cCMV infection. This proportion is markedly higher than the 
proportion of children with CMV detected in the newborn period in the general community 
(approximately 0.6%).2, 16 It is also 6 times greater than the proportion of children with CP who have 
cCMV reported as an attributable cause to the ACPR (1.5%),9 and in a recent retrospective study of 
Caucasian children with CP (1.5%).13 This finding suggests that children with cCMV as indicated by 
CMV DNA in blood in the neonatal period (ie, neonatal CMV viremia) occurs frequently among 
children with CP and suggests that previous reports have underestimated the prevalence of cCMV 
among this population. 
We explored whether other factors, such as recruitment bias, could explain the high prevalence of 
neonatal CMV viremia in our study population of children with CP. There were no differences 
between clinical characteristics of the study population and population-based CP 
registers.9 Similarly, the proportion of children with confirmed or probable cCMV reported to the 
register as an attributable cause in this study (1.2%) was comparable with the value reported in our 
previous study of ACPR data (1.5%).9 We did not identify cross-contamination of CMV DNA between 
samples in our testing owing to the rigorous protocols used. However, we cannot exclude the 
possibility of cross-contamination at the time the NBSC samples were collected and the dried filter 
cards were stored. However, given that the frequency of cCMV is low in our population (estimated 
at 0.6%),2, 16 this occurrence is unlikely. Further, all CMV DNA positive NBSCs were retested using a 
new card sample and a second testing methodology to further validate these results, with 90% 
agreement. We defined our cCMV DNA-positive group using the first methodology because this is a 
highly sensitive, validated diagnostic method. Even if we used the second, less sensitive 
methodology to define our cCMV population, we will still have identified an unexpectedly high 
prevalence (8.7%; 95% CI, 6.1-12.2) of cCMV in this group of children with CP. 
These findings still may underestimate of the proportion of children with cCMV and CP. We used 
retrospective NBSC dried blood samples for CMV DNA because it is the only means of testing for 
cCMV beyond the first 3 weeks of life. However, this method has a low sensitivity for detecting 
cCMV. It is estimated that only 40% of infants with cCMV have virus in their blood in the early 
neonatal period when NBSC are collected, compared with the proportion with virus detectable in 
saliva (>95%) and urine (95%).17, 18 Although a positive cCMV result from the NBSC can be used to 
accurately confirm cCMV infection, a negative result does not rule out cCMV, but rather may 
indicate an absence of CMV viremia or a low viral load at the time of sampling.18, 19, 20 Notably, of the 
4 children in this study whose treating clinicians had previously reported cCMV as an attributable 
cause of their CP validated by laboratory records, 2 had negative NBSC test results. The likely 
explanation for this disparity relates to the low sensitivity of retrospective testing for NBSC for 
cCMV, as explained. 
Examination of the registry data in both cCMV-positive and cCMV-negative groups showed that the 
majority (91.7%) of the cCMV-positive group had spastic CP, similar to our previously published 
report.9 However, in contrast with our previous study, children with spastic quadriplegia were not 
over-represented in the CMV-positive group. Similarly, we found no group differences in relation to 
maternal characteristics or infant sex. The reported comorbidities across the 2 groups also were 
similar, with 1 exception; epilepsy was observed in significantly higher proportions among the cCMV-
positive group. This finding was not unexpected; epilepsy has been reported frequently as an 
outcome of cCMV21, 22, 23 and was over-represented among the cCMV group in previous 
study.9 Overall, however, the cCMV-positive group in this study had a much less severe disability 
profile than the cCMV group reported in our previous paper.9 This suggests that cCMV is 
underascertained in the newborn period in the absence of neonatal screening. Infants diagnosed 
with asymptomatic cCMV infection do not usually develop significant neurologic disabilities, aside 
from sensorineural hearing loss.2, 24 In this study, we could not determine if the children were 
symptomatic for congenital infection in the neonatal period because the CP registers do not include 
this specific data field. There were also no available neuroimaging data. Our findings, therefore, 
suggest that cCMV among infants with mild symptomatic cCMV disease are not always being 
diagnosed clinically early in life. 
Our study has limitations. First, it was not possible to test the NBSCs of all children with CP reported 
to the 2 state CP Registers, because this requires parental consent. Thus, provision of consent may 
have introduced a recruitment bias. Further, not all consented participants had an available NBSC. 
Some cards likely were destroyed after 18 years, as is the legislated standard practice. The impact of 
including the missing NBSC cases on the clinical profile of the cCMV-positive group is unknown, but 
we consider it unlikely that their inclusion would have altered our findings greatly because there was 
not an over-representation of cases of severe CP, or cCMV as an attributable cause, in this group. 
This study serves as a timely reminder of the importance of CMV as a common intrauterine viral 
infection in developed countries and the potential for long-term consequences beyond the newborn 
period.8 Additional research is required to better understand the mechanisms involved in cCMV 
infection as a risk factor for CP and to determine the relative contribution of cCMV on the causal 
pathways to CP. This information is important to further inform policy and practice for neonatal 
screening, and the implementation of both primary4 and secondary prevention7 strategies. A large 
prospective study of CMV would overcome many of the limitations of this study and future research 
should include an examination of the relationship between cCMV and other risk factors among this 
group of children with cCMV and CP, including but not limited to genetic factors, congenital 
abnormalities, maternal history, and the presence of neonatal signs of cCMV. 
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Professor Veronica Wiley, Dr Tiffany Wotton, and the New South Wales (NSW) Newborn Screening 
Laboratory; Dr Simon Paget and the Kids Rehab (Children's Hospital at Westmead); staff at the 
Cerebral Palsy Alliance; the NSW and Australian Capital Territory Cerebral Palsy Registers, in 
particular Isabelle Balde; and most importantly, all of the families and children with CP who made 
this study possible. 
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Figure 
Participant recruitment and availability of stored newborn screening cards. 
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